Pertussis - Annual Epidemiological Report for 2017
In 2017, 42 242 cases of pertussis were reported in EU/EEA countries. Five countries (Germany, the Netherlands, Poland, Spain and the UK) accounted for 76% of all notified cases.
External quality assessment for the detection of Bordetella pertussis by PCR, 2018
This report presents the results of the second European Pertussis Laboratory Surveillance Network (EUPert-LabNet) EQA scheme for Bordetella pertussis PCR funded by ECDC on behalf of EUPert-LabNet. The EQA study was conducted between February and March 2018.
Pertussis - Annual Epidemiological Report for 2016
In 2016, 48 446 cases of pertussis were reported in 30 EU/EEA countries.
Are we missing respiratory viral infections in infants and children? Comparison of a hospital-based quality management system with standard of care
Alchikh, M., Conrad, T., Hoppe, C., Ma, X., Broberg, E., Penttinen, P., Reiche, J., Biere, B., Schweiger, B., Rath, B.
Management and control of communicable diseases in schools and other child care settings: Systematic review on the incubation period and period of infectiousness
Czumbel, I., Quinten, C., Lopalco, P., Semenza, J.C.
External quality assessment scheme for Bordetella pertussis serology 2016
This external quality assessment (EQA) to assess the ability of national reference laboratories from EU/EEA Member States to correctly perform laboratory serodiagnostic tests for pertussis was a collaborative study organised from February to April 2016.
Pertussis - Annual Epidemiological Report 2015
In 2015, 40 195 cases of pertussis were reported by 29 EU/EEA countries.
Pertussis - Annual Epidemiological Report 2016 [2014 data]
In 2014, 40 727 cases of pertussis were reported to TESSy by 29 EU/EEA countries. The notification rate was 9.1 cases per 100 000 population, higher than in 2013, but lower than in the epidemic year of 2012.
Rapid Risk Assessment: Shortage of acellular pertussis-containing vaccines and impact on immunisation programmes in the EU/EEA - 1st update, 3 February 2016
This Rapid Risk Assessment focuses on acellular pertussis-containing combination vaccines used in national vaccination programmes in the EU/EEA Member States.